What is the recommended diagnostic workup for suspected renovascular disease?

Diagnostic Workup for Renovascular Disease

Duplex Doppler ultrasound (DUS) is the recommended first-line imaging modality for suspected renovascular disease, followed by CT angiography (CTA) or MR angiography (MRA) if DUS is suspicious or inconclusive 1.

Clinical Features Warranting Investigation

Before ordering imaging, identify high-risk clinical features that increase suspicion for renovascular hypertension 2:

• Age-related red flags: New hypertension onset after age 50 OR significant hypertension (diastolic >110 mmHg) in patients <35 years
• Hypertension characteristics: Malignant/accelerated hypertension, sudden worsening of previously controlled hypertension, or refractory hypertension despite multiple agents
• Medication response: Deterioration of renal function after starting ACE inhibitors or ARBs
• Physical findings: Abdominal bruit
• Comorbidities: Generalized atherosclerotic disease with hypertension

Imaging Algorithm

Step 1: Duplex Doppler Ultrasound (First-Line)

DUS is advantageous because it requires no contrast, can be used regardless of renal function level, and is noninvasive 2, 1. Key diagnostic parameters include:

• Peak systolic velocity (PSV): Threshold of 200 cm/s (sensitivity 73-91%, specificity 75-96%) 2
• Renal-aortic ratio (RAR): Threshold of 3.5 indicates significant stenosis 2
• Resistance index: Values >0.8 suggest poor kidney viability and predict poor response to revascularization 1
• Kidney size: <7 cm indicates non-viability 1

Common pitfalls with DUS: Patient body habitus, bowel gas, dense atherosclerotic plaques, and accessory renal arteries can limit visualization. DUS may miss 14-15 accessory/polar arteries 2, 3.

Step 2: CTA or MRA (If DUS Suspicious or Inconclusive)

When DUS suggests stenosis or is technically inadequate, proceed to CTA or MRA 1. Both modalities have comparable high accuracy:

• CTA: Sensitivity 94%, specificity 93%, negative predictive value 99% 3, 4
• Gadolinium-enhanced 3D MRA: Sensitivity 90%, specificity 94.1%, negative predictive value 98% 3, 4

Selection between CTA and MRA:

• CTA preferred: Better visualization of calcified plaques, faster acquisition, more widely available
• MRA preferred: Impaired renal function (though contrast-induced nephropathy risk from CTA is lower than previously thought 2)
• Noncontrast MRA protocols: Alternative for severe renal impairment to avoid nephrogenic systemic fibrosis 2

Both modalities can assess aortic disease, accessory renal arteries, and other causes of secondary hypertension (e.g., pheochromocytomas) 2.

Step 3: Conventional Angiography (Confirmation and Intervention)

Digital subtraction angiography is reserved for:

• Therapeutic intervention (angioplasty/stenting)
• Major discrepancies between clinical presentation and noninvasive imaging 3
• Not routinely needed for diagnosis alone 2, 5

Assessment of Kidney Viability

Before considering revascularization, assess kidney viability using these criteria 1:

Signs of viability (favorable for intervention):

• Kidney size >8 cm
• Distinct cortex >0.5 cm with preserved corticomedullary differentiation
• Albumin-creatinine ratio <20 mg/mmol
• Resistance index <0.8

Signs of non-viability (poor revascularization candidates):

• Kidney size <7 cm
• Loss of corticomedullary differentiation
• Albumin-creatinine ratio >30 mg/mmol
• Resistance index >0.8

Defining Significant Stenosis

Hemodynamically significant stenosis is defined as:

• Anatomic: >50-60% luminal narrowing on angiography (though perfusion pressure typically isn't reduced until >70-75% stenosis) 2
• Functional: Mean pressure gradient >10 mmHg at rest, systolic hyperemic gradient >20 mmHg, or renal Pd/Pa ≤0.9 1

The ultimate criterion for renovascular hypertension is blood pressure improvement after intervention 2.

Follow-Up After Diagnosis

For conservatively managed patients, monitor with 1:

• Laboratory assessment of renal function
• Office and out-of-office BP monitoring (ambulatory or home)
• DUS at regular intervals (preferred imaging modality for surveillance)

After renal artery stenting, follow-up at 1 month, then every 12 months, or when new symptoms arise 1.

Obsolete Tests

Do not use:

• Intravenous urography (historical only) 2
• Captopril renography has been largely replaced by DUS, CTA, and MRA 5, 4